Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck and Pfizer Enter Worldwide Collaboration Agreement

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Agreement to develop and commercialize ertugliflozin, an investigational medicine for type 2 diabetes.

Merck & Co., Inc., known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. have announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Ertugliflozin is Phase III ready, with trials expected to begin later in 2013.

“We are pleased to join forces with Merck in the battle against type 2 diabetes and the burden that it poses on global health,” said John Young, president and general manager, Pfizer Primary Care.

Young continued, “Through this collaboration, we believe we can build on Merck’s leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists.”

Under the terms of the agreement, Merck, through a subsidiary, and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and JANUVIA® (sitagliptin) tablets.

Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products.

Pfizer has received an upfront payment and milestones of $60 million and will be eligible for additional payments associated with the achievement of pre-specified future clinical, regulatory and commercial milestones.

Merck and Pfizer will share potential revenues and certain costs on a 60/40 percent basis.

“Merck continues to build upon our leadership position in the oral treatment of type 2 diabetes through our own research and business development,” said Nancy Thornberry, senior vice president and Diabetes and Endocrinology franchise head, Merck Research Laboratories.

Thornberry continued, “We believe ertugliflozin has the potential to complement our strong portfolio of investigational and marketed products, and we look forward to collaborating with Pfizer on its development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.
Agreement aims to develop and commercialize candidates targeting aldosterone synthase for the treatment of cardiovascular disease.
Wednesday, May 19, 2010
Xenon Enters Cardiovascular Disease Collaboration with Merck
The collaboration is aimed to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease.
Thursday, June 25, 2009
Ambrx and Merck Serono Expand Collaboration through Drug Development Alliance
The global strategic collaboration aims to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.
Thursday, February 26, 2009
Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co.
The collaboration aims to develop a therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 for the treatment of type 2 diabetes.
Thursday, December 20, 2007
Merck to Acquire NovaCardia to Boost Clinical Pipeline of Cardiovascular Drug Candidates
Acquisition gives Merck access to KW-3902, an investigational phase 3 compound for acute congestive heart failure.
Thursday, July 26, 2007
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
New Skin Cancer Drugs with Surprising Powers
Inserm team synthesizes and developed new drugs for melanoma.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!